PTC Therapeutics (PTCT) announced that the U.S. FDA has issued a Complete Response Letter related to the New Drug Application for vatiquinone for the treatment of children and adults living with Friedreich’s ataxia. “We are of course disappointed by the FDA’s decision to not approve vatiquinone,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. “We believe the data collected to date demonstrate that vatiquinone could provide a safe and effective therapy for both children and adults living with Friedreich’s ataxia. We plan to meet with the FDA to discuss potential steps to address the issues raised in the CRL.” The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional adequate and well-controlled study would be needed to support NDA resubmission.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Earnings Call Highlights Sephience Success
- PTC Therapeutics price target lowered to $70 from $72 at Baird
- PTC Therapeutics price target raised to $56 from $52 at TD Cowen
- PTC Therapeutics price target raised to $63 from $60 at RBC Capital
- PTC Therapeutics price target raised to $79 from $78 at Wells Fargo